Ce diaporama a bien été signalé.
Le téléchargement de votre SlideShare est en cours. ×

Technologies for cervical cancer lecture


Consultez-les par la suite

1 sur 42 Publicité

Plus De Contenu Connexe

Diaporamas pour vous (18)

Similaire à Technologies for cervical cancer lecture (20)


Plus récents (20)

Technologies for cervical cancer lecture

  1. 1. Technologies for cervical cancer detection, diagnosis, monitoring and treatment in low-resource settings 4th WHO Global Forum on Medical Devices Visakhapatnam, Andhra Pradesh, India
  2. 2. 2 | Agenda  Background  Screen & Treat: technical guidance  Technical Guidance and Specifications – Diagnostics – Treatment  Next Steps
  3. 3. 3 | Cervical Cancer - Disease Context  Primarily caused by persistent Human Papilloma Virus (HPV) infections.  HPV, a DNA virus, has over 100 documented genotypes – 40 of which are known to infect the anogenital tract. – Between 12 and 14 are “high risk” genotypes, those that can cause progression to cancer1.  Cervical cancer is slow-growing. Its progression through precancerous changes provides opportunities for: 1. Prevention; 2. Early detection; and, 3. Treatment  Cervical cancer can be altogether eliminated.
  4. 4. 4 | HPV and Cervical Cancer  Cervical cancer remains one of the gravest threats to women’s lives worldwide;  Cervical cancer is caused by high-risk types of HPV; – HPV 16 and 18: most common high-risk HPV types to cervical cancer – Responsible for approximately 70% of cervical cancer cases.  HPV is currently the most common sexually transmitted infection (STI) – 80% of women can be infected at some point in their lifetime; – Most of infection clear naturally
  5. 5. 5 | Life Course Approach to Cervical Cancer Prevention and Control Girls 9-14 years • HPV vaccination Girls and boys, as appropriate •Health information and warnings about tobacco use •Sexuality education tailored to age & culture •Condom promotion/provision for those engaged in sexual activity •Male circumcision Women > 30 years of age “Screen and treat” – single visit approach • Point-of-care rapid HPV testing for high risk HPV types • Followed by immediate treatment • On site treatment All women as needed Treatment of invasive cancer at any age and palliative care •Ablative surgery •Radiotherapy •Chemotherapy •Palliative Care Primary Prevention Secondary Prevention Tertiary Prevention
  6. 6. 6 | Cervical Cancer: an Avoidable NCD with Gross Inequities
  7. 7. 7 | May 2018: WHO Director General’s Call to Action to Eliminate Cervical Cancer as a Public Health Problem
  8. 8. 8 | Increasing Access to Interventions for control towards elimination 2030 2120 2020 Cervical cancer cases/100,000 2060 Elimination at 4 / 100,000 Elimination by 2085 /2090 Control: Targets of 90% and 70%
  9. 9. 9 | 2020-2030 Acceleration plan towards elimination The 2030 targets and elimination threshold are subject to revision depending on the outcomes of the modeling and the WHO approval process Vision: A world without cervical cancer Goal: below 4 cases of cervical cancer per 100,000 woman-years 90% of girls fully vaccinated with HPV vaccine by 15 years of age 70% of women screened with an HPV test at 35 and 45 years of age and 90% managed appropriately 30% reduction in mortality from cervical cancer 2030 TARGETS
  10. 10. 10 | Strategy towards the elimination of cervical cancer as a global public health problem: key outputs by 2030 Guiding principles: life course and public health approach, social justice and equity, integrated people-centered health services Increased coverage of HPV vaccination Increased coverage of screening & treatment of pre- cancer lesions Increased coverage of diagnosis & treatment for invasive cancer and palliative care Accelerators 1 2 3 KEY OUTPUTS
  11. 11. 11 | 5.1 Vaccinate: key component of the comprehensive prevention and control strategy  Two safe, effective vaccines that prevent infections from high-risk HPV types 16 and 18 are presently licensed in most countries.  One of the HPV vaccines (quadri- and nono-valent), also prevents infections from HPV types 6 and 11, which cause 90% of anogenital warts – Introduced in 85 countries by October 2018 – Coverage varies between less than 10% and more than 90%  Vaccines do not cover all cancer-causing HPV types and do not treat pre- existing infections; thus, ongoing screening is mandatory.  Accelerated focus needed in Africa and Southern Asia Target: 90% of girls fully vaccinated w HPV vaccine by 15 years of age *2030 targets & elimination threshold are subject to revision depending on outcomes of the modeling & the WHO approval process.
  12. 12. 12 | 5.2 Screen & Treat: reduces loss to follow-up, and can reduce the time lag for women to receive treatment  Early detection by screening all women in the target age-group, followed by treatment of detected precancerous lesions, can prevent the majority of cervical cancers.  Cervical cancer screening should be performed at least once for every woman in the target age group where most benefit can be achieved.  Devices that can detect HPV, cytology and VIA play an important role in cervical cancer prevention programs.  Accordingly, effective and appropriate technologies for the treatment of precancerous lesions be used: LEEP, cryotherapy, or thermal ablation. Target: 70% of women screened with an HPV test at 35 and 45 years of age & 90% of the one screened positive managed appropriately *2030 targets & elimination threshold are subject to revision depending on outcomes of the modeling & the WHO approval process.
  13. 13. 13 | 5.3 Invasive Cancer Management  Women diagnosed with early invasive cervical cancer can usually be cured with effective treatment.  It is important for health-care providers at all levels to be able to recognize and promptly manage common symptoms and signs of cervical cancer.  The definitive diagnosis of invasive cervical cancer is made by histopathological examination of a biopsy.  Treatment options include surgery, radiotherapy and chemotherapy; these may be used in combination. If left untreated, invasive cervical cancer is almost always fatal. Target: 30% reduction of mortality from cervical cancer
  14. 14. 14 | WG 3 WHO Recom- mendations (internal only) Technical Task Team (Membership: WHO Co-Chair; invitations to agencies and partners to join the 7 Working Groups) WG 5 Increasing Access to Inter- ventions WG 7 Research WG 6 Monitoring and Surveillance WG 4 Impact Modeling, Costing and Financing WG 2 Advocacy com- munications, & civil society mobilization and engagement WG 1 Cervical Cancer Elimination Strategic Documents and Action Plan Working Groups: Taking Forward the Roadmap of Activities and Stakeholder Coordination 5.1 Vaccines 5.2 Screening & Treatment 5.3 Invasive Cancer Manage- ment
  15. 15. 15 | Agenda  Background  Screen & Treat: technical guidance  Technical Guidance and Specifications Chapters – Diagnostics – Treatment  Next Steps
  16. 16. 16 | Screen & Treat Technical guidance and specifications - why?  A key gap identified was the lack of technical guidance and specifications for the majority of cervical cancer related tests and treatment technologies.  Technical specifications and guidance documents are critical in facilitating the procurement, supply, or use of quality, appropriate technologies.  A strong focus of these documents will be the application in resource- limited settings where existing guidance (if at all) is limited or contextually unsuitable.
  17. 17. 17 | Screen & Treat Technical guidance and specifications – what?  Current efforts will cover technical guidance and specifications for the diagnostics and treatment of precancerous lesions for the prevention of cervical cancer in terms of: – Quality – Performance – Operational characteristics
  18. 18. 18 | Screen & Treat Technical guidance and specifications – how?  These will be useful for Policy- makers, Managers, Procurement officers, Professional health workers, and even manufacturers for: – Procuring; – Supplying; or, – Using devices for treating cervical precancer.  These documents will fit into the WHO repository of resources, to be used alongside:
  19. 19. 19 | Agenda  Background  Screen & Treat: technical guidance  Technical Guidance and Specifications Chapters – Diagnostics – Treatment  Next Steps
  20. 20. 20 | Outline for the forthcoming Technical Guidance and specification document  Section 1: Screening and Diagnosis – HPV NAT IVD – VIA – Colposcope  Section 2: Treatment – Thermal Ablation – Cryotherapy – LEEP  Section 3: Additional information – WHO Infection Prevention and Control – Procurement guidance – Technical knowledge gaps or areas identified for further research WHO technical guidance & specifications Medical devices for the diagnosis and treatment of pre-cancerous lesions for the prevention of cervical cancer
  21. 21. 21 | HPV NAT IVD (1 of 4): Background  Because HPV is the causative agent of cervical cancer, detection of HPV has the potential to improve cervical cancer prevention programs  HPV is a relatively small double stranded DNA virus that is present and accessible in infected exfoliated cell specimens, allowing detection by molecular nucleic acid tests (NAT) that utilize primers and probes to amplify DNA or RNA targets  HPV NATs for qualitative detection of high risk genotypes cover a range of specifications: – DNA and RNA-based technologies • rtPCR, probe hybridization, invader signal, microarray PCR, TMA, NASBA – Reporting out pooled and/or individual genotypes – Internal controls for sample adequacy and to rule out inhibitory substances – Manual, high throughput automated and point-of-care methodology
  22. 22. 22 | HPV NATs (2 of 4): Considerations When Implementing  Specimen acquisition: – Health-care provider collected • Need for exam table/light, specula, gloves, sterilization equipment – Self-collected • In clinic or home-based  Performance of NATs: – Laboratory or point-of-care – Infrastructure and equipment considerations • Are electricity, running water, refrigeration/freezing required? • Possible need for specimen racks, pipettes/tips, centrifuge, heating blocks, disinfectants – Workflow: batch or single samples, throughput requirements  Interpretation of Results – Health-care provider training in interpretation and next steps essential
  23. 23. 23 | HPV NATs (3 of 4): Strengths and Limitations  HPV NATs have the potential to improve cervical cancer prevention programs by improving sensitivity of precancer detection  Provide objective screening results  Allow for self-collected sampling  Workflow flexibility: – Laboratory- vs clinic-based – Manual, automated or point-of-care platforms  Infrastructure requirements and equipment may not be accessible in LRS  Need for trained health-care providers and laboratory personnel
  24. 24. 24 | HPV NAT IVD (4 of 4): Technical Specification Guidance  Clinical Performance: – At least 90% of sensitivity of the designated comparator for detection of CIN2 or greater – Not less than 98% of specificity of the designated comparator – lower bound of agreement not less than 87% for inter- and intra-laboratory reproducibility  Analytic performance: – Sensitivity: (Limit of Detection) dependent on genotype detected, characteristics of particular test – Specificity: cross-reactivity with a panel of organisms (to include those common to female urogenital tract) and low risk HPV genotypes; assessment of effect of endogenous and exogenous interfering substances in cervical specimens  Operational requirements – Infrastructure, equipment, specimen throughput, reagent storage, waste disposal: key considerations that are dependent on particular test and need to be addressed
  25. 25. 25 | VIA (1 of 2): Background  Visual Inspection with Acetic Acid (VIA) is a technique for the detection of pre-cancerous or cancerous lesions in the cervix.  The application of dilute acetic acid on such lesions triggers whitening of these regions.  VIA is a relatively simple, low-cost method presenting immediate results.  A positive result can be followed by immediate treatment (i.e. single-visit approach).  VIA is subjective and depends on the skills and experience of the provider. VIA Screening Results: Negative Positive Image source: Jhpiego, 2015
  26. 26. 26 |  Glacial (water-free) acetic acid is the base for this medium; household white vinegar is another source of concentrated acetic acid.  A 5% acetic acid solution must be used.  A pharmacist, chemist or chemical supplier can make dilute (5%) acetic acid according to the following: – Use glacial acetic acid (water-free acetic acid) or acetic acid with known concentration (above 5%) Total parts of water = [% concentrate/% dilute] − 1 – E.g. preparing a 5% solution from a 20% concentrated acetic acid solution: Total parts of water = 20% 5% − 1 = 3 → 3 parts water to 1 part concentrate, by volume VIA (2 of 2): Technical Specification Guidance
  27. 27. 27 | Colposcope (1 of 3): Background  A colposcope is an instrument that provides strong light and magnifies a field, allowing specific patterns in the epithelial (surface) layer and surrounding blood vessels to be examined.  Colposcopes are used on patients with positive screening results, to: – verify the presence, extent, and type of pre-cancer or cancer; – to guide biopsies of any areas that appear abnormal; and, – to help determine more appropriate treatment (cryotherapy, LEEP, or TA).  Colposcopy requires highly trained providers and is not an appropriate screening tool, nor is colposcopy a required step between screening and treatment.  More recently, colposcopes are being designed as handheld, specialized video or digital camera tools.
  28. 28. 28 | Colposcope (2 of 3): Strengths and limitations  Colposcopy can be used to guide a biopsy of an abnormal area.  Colposcopes are expensive, specialized pieces of equipment.  Colposcopy is resource intensive; it requires provider training, specialized equipment and pathology services.  It should not be used as a screening method.  If the procedure is not readily available, this can create bottlenecks in the system, leading to patients being lost to follow-up.
  29. 29. 29 | Colposcope (3 of 3): Technical Specification Guidance  Optical magnification: 2x-15x, continuous or discrete.  Working distance: 300 mm.  Manual or autofocus.  Colposcope head including eyepiece distance should be high and maneuverable.  Must be attached to a stand or easily fixed onto a stand for hands-free visualization during treatment.  Light source: halogen or LED, with green light filter.
  30. 30. 30 | Thermal Ablation (1 of 3): Background  Thermal ablation has been used effectively in some settings for many years, especially for the treatment of endometriosis.  Thermal ablation uses low heat to destroy lesions.  It has limited side-effects, is inexpensive compared with other treatment options, it is not dependent on a continuous supply chain, and is technically simple to implement.  Only recently have handheld devices come on the market, making the method more suitable for LRS (benchtop models are cumbersome and reliant on mains, though highly effective).  Thermal ablation can be performed immediately after screening, by a range of trained healthcare providers across all levels of health systems.
  31. 31. 31 | Thermal Ablation (2 of 3): Strengths and limitations  The equipment is simple & relatively inexpensive.  External gas is not required.  Electricity is not necessarily required; can function off of portable batteries/power-supply.  In the context of a screen & treat approach, a screen-positive result can be followed by an offer of treatment at the same visit, maximizing treatment coverage and reducing loss to follow-up.  This treatment method does not produce a specimen for pathological examination.
  32. 32. 32 | Thermal Ablation (3 of 3): Technical Specification Guidance  Handheld (rechargeable) or benchtop (plug-in)  Compatible for use with at least two probes with different-sized tips – Standard tip diameters: 16 mm and 19 mm – A flat tip and a tip with a nipple for placement into the cervical canal  Heat to 100-120°C and has a depth penetration of 4-7mm  Typical duty cycle: – 8 seconds of heat up; – 20-45 seconds of treatment; and – 10 seconds to cool down.  Tips should be easily decontaminated, cleaned, and sterilized or disinfected between patients.
  33. 33. 33 | Cryotherapy (1 of 3): Background  Cryotherapy eliminates precancerous areas on the cervix by applying a highly cooled metal disc (cryoprobe) to the cervix and freezing the abnormal areas (along with normal areas) covered by it.  Supercooling of the cryoprobe is accomplished using a coolant gas (either compressed carbon dioxide, CO2, or nitrous oxide, N2O), thus relies on a complex supply chain.  Cryotherapy can be performed immediately after screening, usually by a wide range of trained health care providers across all levels of the health system, and has long been the standard in LRS.  It takes ~15 minutes and is generally well tolerated, associated with only mild discomfort, and thus does not require anaesthesia. The treated area takes about a month to regenerate.
  34. 34. 34 | Cryotherapy (2 of 3): Strengths and limitations  The equipment is simple & relatively inexpensive.  Electricity is not required.  In the context of a screen & treat approach, a screen-positive result can be followed by an offer of treatment at the same visit, maximizing treatment coverage and reducing loss to follow-up.  This treatment method does not produce a specimen for pathological examination.
  35. 35. 35 | Cryotherapy (3 of 3): Technical Specifications Overview  Can be consoles or stand-alone or handheld units.  The probe has a closed system in which the cryogen travels to and circulates in the probe head, then back through probe for exhausting. (An open system is not suitable for CO2 and N2O)  Contact between supercooled metal probe tip and epithelium results in tissue necrosis. The following table indicates treatment temperatures: Source: Colposcopy and Treatment of Cervical Cancer, IARC 2017
  36. 36. 36 | LEEP (1 of 3): Background  LEEP – Loop Electrosurgical Excision Procedure – is the removal of abnormal areas from the cervix and the entire transformation zone using: – A thin wire loop powered by an electrosurgical unit (ESU), which cuts and coagulates at the same time; after which, – A ball electrode is used on the tissue to complete the coagulation. – Tissue removed can be sent for examination to the histopathology laboratory, allowing the extent of the lesion to be assessed.  The procedure can be performed under local anesthesia on an outpatient basis and usually takes 10-15 minutes; however, a patient should stay in- facility for a few hours to assure bleeding does not occur. 3 2 1 3 2 1
  37. 37. 37 |  LEEP is a relatively simple surgical procedure, but it should only be performed by an intensively trained health-care provider with demonstrated competence in the procedure  Recognizing and managing intraoperative and postoperative complications, such as bleeding or infection is crucial; LEEP is best carried out in at least secondary-level facilities where backup care is available.  The histology specimen can have charred borders, making lesion margins difficult to interpret.  LEEP: – Relies on dependable, quality power supply – Uses sophisticated equipment that requires maintenance. LEEP (2 of 3): Strengths and limitations
  38. 38. 38 | LEEP (3 of 3): Technical Specifications Overview  Equipments needed: ESU (with probes), colposcope, optional (UPS), speculum  ESU specification for LEEP: – Reliable power supply. Metal casing case. Foot pedal control – Function: • coagulation mode: up to 80 W / 150 Ω, cutting mode: up to 110 -200 W / 300 -400 Ω; • LEEP specific: blended current option available, coagulation maximum > 60 W, cutting maximum > 60 W. – Electrode: wired, various sizes and shapes (minimum ball electrode, square loop electrode, semicircular loop electrode), made of stainless steel or tungsten wire. WHO comprehensive guide to cervical cancer control, 2014
  39. 39. 39 | Agenda  Background  Screen & Treat: technical guidance  Technical Guidance and Specifications Chapters – Diagnostics – Treatment  Next Steps
  40. 40. 40 | Current timeline •Develop comprehensive draft Draft Review Document finalization Print Consultants will author individual chapters and WHO will compile chapters into a single comprehensive draft. The final document will be sent to print. There are two review cycles: 1)During the Global Forum for Medical Devices; and, 2)Review by GMTA/ HTAi & expert group Authors will address questions, comments and/or concerns raised during the review. After which WHO will work on layout, design, technical editing and proofing. Nov-Dec 2018 Dec-Jan 2019 Jan-Feb 2019 25 Feb 2019
  41. 41. 41 | Output: A new technical guidance and specification document!
  42. 42. 42 | Next steps  To follow will be technical guidance and specifications for diagnostics and technologies for invasive cervical cancer treatment: – Surgical procedures; – Radiotherapy; and, – Chemotherapy.

Notes de l'éditeur

  • 1. Oncogenic types: HPV 16, 18, 31, 35, 39, 45, 51, 52, 54, 56, 58, 59, and with limited evidence for HPV 66 and 68 (IARC ref)
  • The strategic direction 2, highlights the 3 key WHO recommendations to be implemented at scale in countries based on a life course approach, as represented on this figure:
    - HPV vaccination;
    - Screening and treatment;
    - Treatment of cancer and access to palliative care.

    For vaccination, the vaccine group in WHO is currently looking at new evidence available to update the recommendation if needed, and to present findings to the next SAGE meeting

    For screening and treatment: new recommendations are going to be published on thermal ablation and screening amog HIV positive women. The strategy will focus on the extensive implementation of one of the recommended algorithm: HPV testing followed by immediate treatment for women tested positive in a single visit approach

    As more cancer will be identified in the context of an intensive screening campain, strengthen access to reatment and palliative care is essential
  • 528,000 new cases
    266,000 death
    90 % of the deaths in LMIC

    Cervical cancer is an unacceptable disease and the burden is still far too high in many countries, principally in middle and low income countries,
    reflecting the many inequities across the world in terms of access to services.
    High income countries have addressed the burden with organized screening programmes and now the low cx ca incidence can be maintained by the introduction of vaccines
  • So the call to action made on 19 May by the WHO Director-General is critical to define a path forward and engage with partners and member states, to overcome the challenges and scale-up cost-effective interventions.

    Coordinated action globally is needed to eliminate cervical cancer.

    Already many partners have endorsed this call to action, as per the many logo you can see on this slide, but we are also reaching out to more partners to join forces.
    As many partners are already working towards contributing to this goal, the key message of the call to action was that this should be done in a more coordinated manner in order to accelerate progress.

    The WHO DG Recognized that several countries and UN agencies have already moved forward under the UN Global Joint Programme on Cervical Cancer Prevention and Control, however, he insisted that to succeed, we need everyone on board, and that we must expand our partnership to include anyone and everyone who can help us reach our goal.
  • Question: What will different models tell us when and how global cervical cancer elimination can be reached under the most optimistic and aspirational assumptions?
  • Work is on going presently to define the goal for elimination; and the core impact indicator to measure elimination will be cervical cancer incidence.

    We are also working on the targets to be reached at different points in time for two core process indicators:
    - HPV vaccination coverage,
    - and screening coverage w HPV tests, assuming that 90% of women screened positive will be managed appropriately;

    In addition the impact on mortality from cervical cancer will be measured

    The indicators and targets on this slide are the one that appear in some of the WHO document and these are presently being revised to the light of elimination context

    What the Flagship will achieve by 2023
    • Deliver on the GPW target of a 50% coverage of HPV vaccine (also an SDG indicators).
    • Contribute to the following GPW targets:
    • (i) a 20% relative reduction in premature mortality from NCDs including cancer through prevention and treatment;
    • (ii) an increase in the availability of oral morphine in facilities caring for patients in need of this treatment for palliative care at all levels from 25% to 50%.
    • The Flagship will also contribute to:
    • (i) the Global STI Strategy target of 70% of countries having introduced HPV by 2020; and
    • (ii) the NCD Global Action Plan target of 25% reduction of premature mortality from NCDs including cancer by 2025 as well as the SDG target of one-third reduction by 2030.

    Achievement of the above targets will also make a significant contribution to scaling up UHC, and to achieve the SDG targets on universal access to SRHR and gender equality and empowerment.
  • Vaccinating girls before initiation of sexual activity is an important primary prevention intervention in a comprehensive cervical cancer prevention and control programme.
    The vaccines do not treat pre-existing HPV infection or HPV-associated disease, which is why vaccination is recommended prior to initiation of sexual activity.
    Because the vaccines do not protect against all HPV types that can cause cervical cancer, girls vaccinated against HPV will still require cervical cancer screening later in their lives.
  • Decisions on which screening and treatment approach to use in a particular country or health-care facility should be based on a variety of factors, including benefits and harms, potential for women to be lost to follow-up, cost, and availability of the necessary equipment and human resources.
  • https://slideplayer.com/slide/6115581/